samedan logo

 
 
spacer
home > ict > summer 2018 > regulatory guidance on outsourcing
PUBLICATIONS
International Clinical Trials

Regulatory Guidance on Outsourcing

The landmark guidelines for Good Clinical Practice globally were released by the ICH in 1996 – the now-famous ICH GCP E6. This was the culmination of a number of years’ work by the combined efforts of the regulatory agencies and industry associations of Europe, Japan, and the US, along with consideration of practices in Australia, Canada, the Nordic countries, and the WHO. The aim of the guideline was the harmonisation of regulatory requirements in what was then the regions of the world in which the majority of drug trials were conducted, namely Europe, the US, and Japan.

A review of the guideline reveals that a significant proportion of the document is taken up with describing the roles and responsibilities of various key players in the conduct of a drug trial. Entire sections are given over to the duties of an institutional review board (IRBs)/independent ethics committee (Section 3), an investigator (Section 4), the responsibilities of a sponsor (Section 5), and, within that, the activities associated with monitoring (5.18). The effects of this have been several-fold. The relationship between a sponsor and an investigator has been clearly established and a universal model for how ethics committees/IRBs should be set up and operate has been created. Additionally, the activities associated with monitoring have become the universal blueprint for the job description for a clinical research monitor/associate.

A lot has happened in the clinical research sector since the release of E6. The growth and widespread use of electronic data capture was one of the factors behind the release of EMA’s Reflection Paper on Risk Based Quality Management in Clinical Trials in 2013. Included in the glossary of this document is the definition of central monitoring, a concept that was not readily achievable in 1996 because of the reliance on predominantly paperbased data capture systems at the time. Also, in 2013 and in response to the advances in data capture, the FDA produced its Guidance for Industry, ‘Oversight of Clinical Investigations: A Risk-Based Approach to Monitoring’. As with the EMA document, the subject of centralised monitoring is comprehensively covered, including a list of alternative monitoring techniques.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Martin Robinson is Co-Founder and Executive Vice President at IAOCR. He has worked across the international biopharmaceuticals industry for nearly 30 years, and his extensive experience includes setting up a number of clinical research business ventures. Using his clinical operations and workforce development expertise, Martin is a leading expert in clinical research competence, at an individual and organisational level.
spacer
Martin Robinson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

[Pamplona, November 26 2019] 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment.
More info >>

White Papers

High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts

ILC Dover

As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
More info >>

 
Industry Events

Evolution Summit

2-4 March 2020, The Meritage Resort & Spa, Napa, CA, USA

The 21st Evolution Summit is an invitation-only, premium Summit bringing leading clinical trial executives and innovative suppliers & solution providers together. The Summit’s content is aligned with key clinical trial challenges and interests, relevant market developments, and practical and progressive ideas and strategies adopted by successful pioneers.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement